[1] Deroo BJ, Korach KS. Estrogen receptors and human disease[J]. J Clin Invest, 2006, 116(3):561-570.  doi: 10.1172/JCI27987
[2] Leung YK, Mak P, Hassan S, et al. Estrogen receptor(ER)-beta isoforms:a key to understanding ER-beta signaling[J]. Proc Natl Acad Sci U S A, 2006, 103(35):13162-13167.
[3] Heldring N, Pike A, Andersson S, et al. Estrogen receptors:how do they signal and what are their targets[J]. Physiol Rev, 2007, 87(3):905-931.
[4] Li X, Huang J, Yi P, et al. Single-chain estrogen receptors(ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways[J]. Mol Cell Biol, 2004, 24(17):7681-7694.
[5] Aranda A, Pascual A. Nuclear hormone receptors and gene expression[J]. Physiol Rev, 2001, 81(3):1269-1304.  doi: 10.1152/physrev.2001.81.3.1269
[6] Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors[J]. Genes Dev, 2000, 14(2):121-141.
[7] Heery DM, Kalkhoven E, Hoare S, et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors[J]. Nature, 1997, 387(6634):733-736.
[8] Zhang H, Thomsen JS, Johansson L, et al. DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors[J]. J Biol Chem, 2000, 275(51):39855-39859.
[9] Ogryzko VV, Schiltz RL, Russanova V, et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases[J]. Cell, 1996, 87(5):953-959.
[10] Koshiishi N, Chong JM, Fukasawa T, et al. p300 gene alterations in intestinal and diffuse types of gastric carcinoma[J]. Gastric Cancer, 2004, 7(2):85-90.
[11] Ding XF, Anderson CM, Ma H, et al. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1(GRIP1)and steroid receptor coactivator 1(SRC-1):multiple motifs with different binding specificities[J]. Mol Endocrinol, 1998, 12(2):302-313.
[12] Voegel JJ, Heine MJ, Tini M, et al. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways[J]. EMBO J, 1998, 17(2):507-519.
[13] Kurebayashi J, Otsuki T, Kunisue H, et al. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer[J]. Clin Cancer Res, 2000, 6(2):512-518.
[14] Blanco JC, Minucci S, Lu J, et al. The histone acetylase PCAF is a nuclear receptor coactivator[J]. Genes Dev, 1998, 12(11):1638-1651.
[15] Giannini R, Cavallini A. Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma[J]. Anticancer Res, 2005, 25(6B):4287-4292.
[16] Yuan CX, Ito M, Fondell JD, et al. The TRAP220 component of a thyroid hormone receptor-associated protein(TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion[J]. Proc Natl Acad Sci U S A, 1998, 95(14):7939-7944.
[17] Kitagawa H, Fujiki R, Yoshimura K, et al. The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome[J]. Cell, 2003, 113(7):905-917.
[18] Li H, Chen JD. The receptor-associated coactivator 3 activates transcription through CREB-binding protein recruitment and autoregulation[J]. J Biol Chem, 1998, 273(10):5948-5954.
[19] Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer[J]. Science, 1997, 277(5328):965-968.
[20] Li D, Desai-Yajnik V, Lo E, et al. NRIF3 is a novel coactivator mediating functional specificity of nuclear hormone receptors[J]. Mol Cell Biol, 1999, 19(10):7191-7202.
[21] Talukder AH, Gururaj A, Mishra SK, et al. Metastasis-associated protein 1 interacts with NRIF3, an estrogen-inducible nuclear receptor coregulator[J]. Mol Cell Biol, 2004, 24(15):6581-6591.
[22] Kim HJ, Yi JY, Sung HS, et al. Activating signal cointegrator 1, a novel transcription coactivator of nuclear receptors, and its cytosolic localization under conditions of serum deprivation[J]. Mol Cell Biol, 1999, 19(9):6323-6332.
[23] Luciano RL, Wilson AC. N-terminal transcriptional activation domain of LZIP comprises two LxxLL motifs and the host cell factor-1 binding motif[J]. Proc Natl Acad Sci U S A, 2000, 97(20):10757-10762.
[24] Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes[J]. Mol Cell Biol, 2000, 20(5):1868-1876.
[25] Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha(PGC-1 alpha):transcriptional coactivator and metabolic regulator[J]. Endocr Rev, 2003, 24(1):78-90.
[26] Zhu Y, Kan L, Qi C, et al. Isolation and characterization of peroxisome proliferator-activated receptor(PPAR)interacting protein(PRIP)as a coactivator for PPAR[J]. J Biol Chem, 2000, 275(18):13510-13516.
[27] Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers[J]. Science, 2006, 314(5797):268-274.
[28] Ko L, Cardona GR, Chin WW. Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator[J]. Proc Natl Acad Sci U S A, 2000, 97(11):6212-6217.
[29] Sauvé F, McBroom LD, Gallant J, et al. CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant[J]. Mol Cell Biol, 2001, 21(1):343-353.
[30] Zhou D, Chen S. PNRC2 is a 16 kDa coactivator that interacts with nuclear receptors through an SH3-binding motif[J]. Nucleic Acids Res, 2001, 29(19):3939-3948.
[31] Gaughan L, Brady ME, Cook S, et al. Tip60 is a co-activator specific for class I nuclear hormone receptors[J]. J Biol Chem, 2001, 276(50):46841-46848.
[32] Kressler D, Schreiber SN, Knutti D, et al. The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha[J]. J Biol Chem, 2002, 277(16):13918-13925.
[33] Meirhaeghe A, Crowley V, Lenaghan C, et al. Characterization of the human, mouse and rat PGC1 beta(peroxisome-proliferator-activated receptor-gamma co-activator 1 beta)gene in vitro and in vivo[J]. Biochem J, 2003, 373(Pt 1):155-165.
[34] Wang Q, Sharma D, Ren Y, et al. A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression[J]. J Biol Chem, 2002, 277(45):42852-42858.
[35] Clark J, Edwards S, John M, et al. Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones[J]. Genes Chromosomes Cancer, 2002, 34(1):104-114.
[36] Barletta F, Wong CW, Mcnally C, et al. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc[J]. Mol Endocrinol, 2004, 18(5):1096-1108.
[37] Vadlamudi RK, Manavathi B, Balasenthil S, et al. Functional implications of altered subcellular localization of PELP1 in breast cancer cells[J]. Cancer Res, 2005, 65(17):7724-7732.
[38] Mo R, Rao SM, Zhu YJ. Identification of the MLL2 complex as a coactivator for estrogen receptor alpha[J]. J Biol Chem, 2006, 281(23):15714-15720.
[39] Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions[J]. Science, 2009, 325(5942):834-840.
[40] Chen M, Ni J, Chang HC, et al. CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells[J]. Carcinogenesis, 2009, 30(5):841-850.
[41] Khurana S, Chakraborty S, Cheng XW, et al. The actin-binding protein, actinin alpha 4(ACTN4), is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells[J]. J Biol Chem, 2011, 286(3):1850-1859.
[42] Heery DM, Hoare S, Hussain S, et al. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors[J]. J Biol Chem, 2001, 276(9):6695-6702.
[43] Teo AK, Oh HK, Ali RB, et al. The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage[J]. Mol Cell Biol, 2001, 21(20):7105-7114.  doi: 10.1128/MCB.21.20.7105-7114.2001
[44] Fernandes I, Bastien Y, Wai T, et al. Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms[J]. Mol Cell, 2003, 11(1):139-150.  doi: 10.1016/S1097-2765(03)00014-5
[45] Martini PG, Katzenellenbogen BS. Modulation of estrogen receptor activity by selective coregulators[J]. J Steroid Biochem Mol Biol, 2003, 85(2-5):117-122.
[46] Meng Q, Zhao Z, Yan M, et al. ERR-10:a new repressor in transcriptional signaling activation of estrogen receptor-alpha[J]. FEBS Lett, 2004, 576(1-2):190-200.
[47] Song KH, Li T, Chiang JY. A Prospero-related homeodomain protein is a novel co-regulator of hepatocyte nuclear factor 4alpha that regulates the cholesterol 7alpha-hydroxylase gene[J]. J Biol Chem, 2006, 281(15):10081-10088.
[48] Rossi M, Colecchia D, Iavarone C, et al. Extracellular signal-regulated kinase 8(ERK8) controls estrogen-related receptor α(ERRα)cellular localization and inhibits its transcriptional activity[J]. J Biol Chem, 2011, 286(10):8507-8522.
[49] Zhang J, Kalkum M, Yamamura S, et al. E protein silencing by the leukemogenic AML1-ETO fusion protein[J]. Science, 2004, 305(5688):1286-1289.
[50] Razeto A, Ramakrishnan V, Litterst CM, et al. Structure of the NCoA-1/SRC-1 PAS-B domain bound to the LXXLL motif of the STAT6 transactivation domain[J]. J Mol Biol, 2004, 336(2):319-329.
[51] Benecke A, Gaudon C, Garnier J M, et al. ADA3-containing complexes associate with estrogen receptor alpha[J]. Nucleic Acids Res, 2002, 30(11):2508-2514.
[52] Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding domains:three-dimensional structures, molecular interactions and pharmacological implications[J]. Trends Pharmacol Sci, 2000, 21(10):381-388.
[53] Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain:structure and function[J]. Curr Opin Cell Biol, 1998, 10(3):384-391.
[54] Feng W, Ribeiro RC, Wagner RL, et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors[J]. Science, 1998, 280(5370):1747-1749.
[55] Baniahmad A, Leng X, Burris TP, et al. The tau 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s)necessary for transcriptional silencing[J]. Mol Cell Biol, 1995, 15(1):76-86.
[56] Bourguet W, Ruff M, Chambon P, et al. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha[J]. Nature, 1995, 375(6530):377-382.
[57] Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen[J]. Cell, 1998, 95(7):927-937.
[58] Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor[J]. Nature, 1997, 389(6652):753-758.
[59] Darimont BD, Wagner RL, Apriletti JW, et al. Structure and specificity of nuclear receptor-coactivator interactions[J]. Genes Dev, 1998, 12(21):3343-3356.
[60] Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma[J]. Nature, 1998, 395(6698):137-143.
[61] Wärnmark A, Treuter E, Gustafsson JA, et al. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha[J]. J Biol Chem, 2002, 277(24):21862-21868.
[62] Klein F, Atkinson RA, Potier N, et al. Biochemical and NMR mapping of the interface between CREB-binding protein and ligand binding domains of nuclear receptor-Beyond the LXXLL motif[J]. J Biol Chem, 2005, 280(7):5682-5692.
[63] Hur E, Pfaff SJ, Payne ES, et al. Recognition and accommodation at the androgen receptor coactivator binding interface[J]. PLoS Biol, 2004, 2(9):E274.
[64] Mcinerney EM, Rose DW, Flynn SE, et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation[J]. Genes Dev, 1998, 12(21):3357-3368.
[65] Gee AC, Carlson KE, Martini PG, et al. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor[J]. Mol Endocrinol, 1999, 13(11):1912-1923.
[66] Rha GB, Wu G, Shoelson SE, et al. Multiple binding modes between HNF4alpha and the LXXLL motifs of PGC-1alpha lead to full activation[J]. J Biol Chem, 2009, 284(50):35165-35176.
[67] Varlakhanova N, Snyder C, Jose S, et al. Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain[J]. Mol Cell Biol, 2010, 30(6):1434-1445.
[68] Heldring N, Pawson T, Mcdonnell D, et al. Structural insights into corepressor recognition by antagonist-bound estrogen receptors[J]. J Biol Chem, 2007, 282(14):10449-10455.
[69] Galande AK, Bramlett KS, Trent JO, et al. Potent inhibitors of LXXLL-based protein-protein interactions[J]. Chembiochem, 2005, 6(11):1991-1998.
[70] Chang Cy, Norris JD, Grøn H, et al. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries:discovery of peptide antagonists of estrogen receptors alpha and beta[J]. Mol Cell Biol, 1999, 19(12):8226-8239.
[71] Rodriguez AL, Tamrazi A, Collins ML, et al. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding[J]. J Med Chem, 2004, 47(3):600-611.
[72] Parent AA, Gunther JR, Katzenellenbogen JA. Blocking estrogen signaling after the hormone:pyrimidine-core inhibitors of estrogen receptor-coactivator binding[J]. J Med Chem, 2008, 51(20):6512-6530.
[73] Gunther JR, Moore TW, Collins ML, et al. Amphipathic benzenes are designed inhibitors of the estrogen receptor alpha/steroid receptor coactivator interaction[J]. ACS Chem Biol, 2008, 3(5):282-286.
[74] Lafrate AL, Gunther JR, Carlson KE, et al. Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor[J]. Bioorg Med Chem, 2008, 16(23):10075-10084.
[75] Phan T, Nguyen HD, Göksel H, et al. Phage display selection of miniprotein binders of the estrogen receptor[J]. Chem Commun(Camb), 2010, 46(43):8207-8209.
[76] Shao D, Berrodin TJ, Manas E, et al. Identification of novel estrogen receptor alpha antagonists[J]. J Steroid Biochem Mol Biol, 2004, 88(4-5):351-360.
[77] Zhou HB, Collins ML, Gunther JR, et al. Bicyclo[2. 2. 2]octanes:close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators[J]. Bioorg Med Chem Lett, 2007, 17(15):4118-4122.
[78] Hruby VJ, Li G, Haskell-Luevano C, et al. Design of peptides, proteins, and peptidomimetics in chi space[J]. Biopolymers, 1997, 43(3):219-266.
[79] Carraz M, Zwart W, Phan T, et al. Perturbation of estrogen receptor alpha localization with synthetic nona-arginine LXXLL-peptide coactivator binding inhibitors[J]. Chem Biol, 2009, 16(7):702-711.
[80] Moellering RE, Cornejo M, Davis TN, et al. Direct inhibition of the NOTCH transcription factor complex[J]. Nature, 2009, 462(7270):182-188.
[81] Hu XD, Meng QH, Xu JY, et al. BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity[J]. Biochem Biophys Res Commun, 2011, 404(4):903-909.
[82] Sun KK, Zhong N, Yang Y, et al. Enhanced radiosensitivity of NSCLC cells by transducer of erbB2. 1(TOB1)through modulation of the MAPK/ERK pathway[J]. Oncol Rep, 2013, 29(6):2385-2391.